Stereotactic Radiotherapy for Metastasis to the Lung

Phase 2

Recruiting

• Conditions: lung cancer; 10038666; lung malignancy; 10029107; 10038737

• Registration Number: NL-OMON35375
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

The patient is eighteen years or older.
The metastases are limited to a maximum of 2 organs, and one of the 2 is the lung.
The patient has no more than 5 metastatic lesions.
The primary tumor site is locally controlled.
The interval between treatment of the primary tumor and diagnosis of the metastasis is at least four months.
The patient has a life expectancy of at least 6 months.

Exclusion Criteria

Patients with more than 5 metastatic lesions.
Patients with an active primary tumor site.
pregnant women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Local control</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To determine whether treatment related toxicity is acceptable (maximal toxicity<br /><br>grade I-III).<br /><br>To determine prognostic factors on local control, overall survival and<br /><br>progression free survival.</p><br>